Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626520 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla
A Phase 2 study, sponsored by Essentia Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02626520 is a Phase 2 study that was terminated before completion, run by Essentia Health. The registered enrollment target is 11 participants.
The verdict
NCT02626520, a Phase 2 study, was terminated before completion, sponsored by Essentia Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
Patients diagnosed with pancreatic cancer without clinically detectable metastatic disease will be treated with standardized systemic chemotherapy, followed by chemoradiation, and then surgical resection for those with resectable or borderline resectable disease. The primary endpoint is disease-free survival at 1 yr from initiation of treatment.
Interventions
- DRUG Gemcitabine and nanoparticle albumin bound paclitaxel
- DRUG 5-fluorouracil and irinotecan
- RADIATION Preoperative chemoradiation
- PROCEDURE Definitive resection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-05-11 |
| Est. Completion | 2017-09-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02626520
The ClinicalTrials.gov registry entry for NCT02626520 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Essentia Health, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Gemcitabine and nanoparticle albumin bound paclitaxel is the first listed.
NCT02626520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02626520 about?
NCT02626520 is a clinical study titled "Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla". Patients diagnosed with pancreatic cancer without clinically detectable metastatic disease will be treated with standardized systemic chemotherapy, followed by chemoradiation, and then surgical resection for those with resectable or borderline resectable disease. The primary endpoint is disease-free...
What is the current status of trial NCT02626520?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2016-05-11. Estimated completion is 2017-09-14.
What interventions are being tested in trial NCT02626520?
The interventions under investigation include: Gemcitabine and nanoparticle albumin bound paclitaxel (DRUG), 5-fluorouracil and irinotecan (DRUG), Preoperative chemoradiation (RADIATION), Definitive resection (PROCEDURE).
Who is sponsoring clinical trial NCT02626520?
This trial is sponsored by Essentia Health, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.